Skip to contentA
Adaptimmune Therapeutics PLC
A
ADAPYAdaptimmune Therapeutics PLC Q2 2022 · 10-Q
Revenue$5.54M$5.54M+78.9% vs Q2 2021 Net Income-$44.52M-$44.52MN/M vs Q2 2021 EPS Diluted-$0.05-$0.05N/M vs Q2 2021 Operating Income-$43,752,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Adaptimmune Therapeutics PLC · CIK 1621227 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$50,211,000N/M Margins · derivedOperating margin-790.0%+480.1 pt vs Q2 2021
Net margin-803.9%+458.4 pt vs Q2 2021
ended Jun 30, 2022 · filed Aug 4, 2022 · 35 d after period end